comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 01:01:21 - browse：234

Sammy Kimball for STAT

Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Senate panel eyes new effort on drug shortages

entertainment

explore

WSS

Was Amgen transparent enough on FDA's concern on cancer drug?

It's time to get medical device identifiers over the finish line

Leqembi, other new Alzheimer’s drugs require better biomarkers

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

HCA discloses massive data breach affecting 11 million patients

Palantir health business leans on meeting customers’ needs

leisure time

comprehensive

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Chan Zuckerberg Biohub Chicago to focus on inflammation

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Sports medicine is finally prioritizing gender equality

Living with Fabry disease, a condition that causes chronic pain

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA panel signals lack of confidence in Amgen cancer drug data

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Chemotherapy drug shortage eases slightly but still widespread

focus

Bill would stop addiction treatment from triggering child abuse inquiry

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati